Oramed Provides Highlights and Data From Its Phase IIb Oral Insulin Study Investor Event
ORMD-0801 dosed once daily reduced A1C by 0.60% compared to only a 0.06% reduction by placebo ORMD-0801 improves metabolic control as evidenced by significant reduction in A1C levels in patients with type 2 diabetes inadequately controlled on multiple other standard of care drugs NEW YORK, Nov. 19, 2019 /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) […]
